Christophe Boetsch

12PUBLICATIONS
156CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 21, 2026
FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors.

|Nov 18, 2025
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis.

Apolline Lefèvre, Zinnia P Parra-Guillen, Iñaki F Trocóniz

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

|Apr 18, 2025
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.

Jiawen Zhu, Amy Schroeder, Sabine Frank

|Feb 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

Pageof 2

Frequent Collaborators

6 joint publications

Volker Teichgräber

6 joint publications

Jehad Charo

6 joint publications

Stefan Evers

6 joint publications

David Dejardin